Methods of treating gastrointestinal diseases using lidipitant
By administering Sichuan dipitam to gastroparesis patients, a specific plasma concentration is achieved, the problem of insufficient treatment for gastroparesis and other diseases is solved, and gastric motility disorders and related symptoms are significantly improved, providing an effective treatment plan.
Patent Information
- Application Number
- CN202411421827.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2017-11-17
- Filing Date
- 2018-11-16
- Publication Date
- 2024-12-06
AI Technical Summary
The existing gastroparesis treatments lack effective long-term solutions, and patients have serious and troubled symptoms. There is currently no approved long-term treatment for gastroparesis symptoms.
By administering citrustan to patients diagnosed with citrustan responsive gastrointestinal disease, the amount and frequency of 100 ng/mL of plasma concentration was reached and maintained orally in solid quick release form, targeting gastric dynamic disorders, The symptoms of nausea and vomiting caused by chemotherapy, postoperative nausea and vomiting are treated.
Significantly improving gastric motility disorders and related symptoms such as nausea, vomiting, premature fullness, postprandial fullness, indigestion and abdominal pain, provides effective treatment for gastroparesis and other kenapitane-responsive GI diseases.
Smart Images

Figure CN119074729A_ABST
Abstract
Description
[0001] This application is a divisional application. The international application number of the original application is PCT / US2018 / 061593, the Chinese national application number is 201880073477.9, the application date is November 16, 2018, and the name of the invention is "Methods for treating gastrointestinal diseases using chuandipitant".
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims the benefit of co-pending U.S. Provisional Application No. 62 / 587,681, filed on November 17, 2017. Technical Field
[0004] The present invention relates to methods of using trandipitant to treat gastrointestinal diseases. Background Art
[0005] The present application generally relates to the use of NK-1 receptor antagonists. More specifically, the present application relates to the use of the NK-1 antagonist tradipitant in the treatment of certain tradipitant-responsive diseases and conditions, most specifically gastric motility disorders and conditions in which improvement in gastric motility would produce therapeutic benefits.
[0006] Mammalian tachykinins (neurokinins [NK]) are a family of peptide neurotransmitters that share a common C-terminal sequence. This group includes substance P (SP), neurokinin A (NKA), and neurokinin B (NKB). SP exerts its effects by binding to NK receptors: SP preferentially binds to the NK-1 receptor and, with lower affinity, to the NK-2 and NK-3 receptors, which preferentially bind to NKA and NKB, respectively. SP receptors are G protein-coupled receptors, and binding to SP activates several second messenger systems, protein kinases, and transcription factors, including calcium, inositol triphosphate, p42 / 44 and p38 stress-regulated kinases, and protein kinase C.
[0007] SP is the most abundant NK and is involved in regulating many physiological processes; for example, in the intestines and in the bronchial and vascular systems. In the central nervous system (CNS), neurons containing SP are distributed in different neuronal networks. They are found in the midbrain and basal ganglia, hypothalamus, limbic system and spinal cord. SP co-localizes with other neurotransmitters and has neuromodulatory effects. Examples of co-localization are serotonin in the raphe nuclei, dopamine in the midbrain and striatum, gamma-aminobutyric acid (GABA) and acetylcholine (ACh) in the cortex, and corticotropin-releasing hormone in the hypothalamus. Examples of direct neuromodulatory effects of SP are regulation of the release of ACh in the human cortex and regulation of noradrenergic neurotransmission in the locus coeruleus.
[0008] The NK-1 receptor is a potential therapeutic target for the treatment of functional gastrointestinal disorders (FGIDs) such as dyspepsia and irritable bowel syndrome (IBS). FGIDs are diagnosed by the recurrence of abdominal pain or discomfort symptoms, while subjects with IBS often present with diarrhea or constipation. Existing treatments for FGIDs include stress management strategies, dietary modifications, and pharmacotherapy limited to symptomatic treatment. Evidence for the role of neurokinins in abdominal pain has been observed in a double-blind study, in which an NK-1 antagonist (CJ-11,974) reduced the discomfort associated with rectosigmoid distension in patients with IBS. NK-1 and NK-2 receptor antagonists have been studied for their potential use in relieving food allergies and IBS symptoms. The NK-2 receptor antagonist nepadutant (MEN 11420) effectively antagonizes the motility-stimulating effects of neurokinin A without affecting basal gastrointestinal motility.
[0009] Gastrointestinal (or gastric) motility refers to digestion and the muscle coordination contraction that promotes gastrointestinal (GI) tract contents through the gastrointestinal tract. The gastrointestinal tract includes the esophagus, stomach, small intestine and colon, and they each have different motion patterns to complete different functions. The motion or sensitivity abnormality of any one of these segments separated by sphincters of the gastrointestinal tract may cause characteristic symptoms, which may include abdominal distension, recurrent obstruction, abdominal pain, constipation, nausea and vomiting. Gastric motility disorders may include, for example, gastroesophageal reflux disease (GERD), intestinal motility disorders, intestinal pseudo-obstruction, small intestinal bacterial overgrowth, constipation, outlet obstruction constipation (pelvic floor dyssynergia), diarrhea, fecal incontinence, Hirschsprung's disease, gastroparesis and achalasia.
[0010] Gastroparesis is a chronic upper gastrointestinal disorder characterized by objective evidence of delayed gastric emptying, symptoms associated with gastric retention, and the absence of mechanical obstruction. The true prevalence of gastroparesis is unknown, but its prevalence in the United States is estimated to be as high as 5 million. The two main causes of gastroparesis are diabetes and idiopathic diseases, which together account for more than 60% of all cases. Nausea is the most commonly reported symptom of gastroparesis, having been reported in more than 90% of patients in various studies. Vomiting is the second most commonly reported symptom, with a reported incidence of between 66% and 88%. Other common symptoms of gastroparesis include early satiety, postprandial fullness, abdominal pain, and bloating. Symptoms of gastroparesis may also occur in individuals without delayed gastric emptying. Such individuals may be diagnosed, for example, as having symptoms of gastroparesis, or having functional dyspepsia or functional nausea. Despite the severity of symptoms and associated distress in patients with gastroparesis, there is currently no approved treatment for the symptoms of gastroparesis for long-term use.
[0011] Chuandipitant is a highly potent, selective, centrally penetrant and orally active neurokinin 1 (NK-1) receptor antagonist, represented by the following formula I
[0012]
[0013] Tradipitant is disclosed in U.S. Pat. No. 7,320,994 and contains six main structural components: a 3,5-bis-trifluoromethylphenyl moiety, two pyridine rings, a triazole ring, a chlorophenyl ring, and a ketone. Tradipitant is known by the chemical names 2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridyl)-1H-1,2,3-triazol-4-yl]-3-pyridyl](2-chlorophenyl)-methanone and {2-[1-(3,5-bis(trifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone, also known as LY686017 and VLY-686. US Patent 7,320,994 describes methods of using compounds such as trandipitant to treat conditions associated with tachykinin excess, particularly where the conditions associated with tachykinin excess are depression and anxiety.The patent further describes the possibility of using compounds such as tradipitant in other such diseases, namely, because these compounds inhibit the physiological effects associated with an excess of tachykinins, the patent describes the usefulness of such compounds in treating a number of other diseases associated with tachykinin receptor activation, including: psychosis, and schizophrenia and other psychiatric disorders; neurodegenerative diseases, such as dementia, including senile dementia of the Alzheimer's type, Alzheimer's disease, AIDS-related dementia and Down syndrome; demyelinating diseases, such as multiple sclerosis and amyotrophic lateral sclerosis and other neuropathic diseases, such as peripheral neuropathy, diabetic and chemotherapy-induced neuropathy, and post-herpetic neuralgia and other neuralgic pain; acute and chronic obstructive airway diseases, such as adult respiratory distress syndrome, bronchopneumonia, bronchospasm, chronic bronchitis, driving cough and asthma; inflammatory diseases, such as inflammatory bowel disease, psoriasis, fibrositis, osteoarthritis and rheumatoid arthritis; musculoskeletal system diseases, such as osteoporosis; allergies, such as eczema and rhinitis; allergic conditions, such as poison ivy. ivy); eye diseases, such as conjunctivitis and vernal conjunctivitis; skin diseases, such as contact dermatitis, atopic dermatitis, urticaria and other eczematoid dermatitis; addiction disorders, such as alcoholism; stress-related physical disorders; reflex sympathetic dystrophy, such as shoulder / hand syndrome; dysthymia disorder); adverse immune responses, such as rejection of transplanted tissues and diseases associated with immune enhancement or suppression, such as systemic lupus erythematosus; gastrointestinal disorders or diseases associated with visceral neuronal control, such as ulcerative colitis, Crohn's disease, and irritable bowel syndrome; bladder dysfunction, such as bladder detrusor hyperreflexia and incontinence; atherosclerosis; fibrin and collagen diseases, such as scleroderma and eosinophilic fasciitis; irritative symptoms of benign prostatic hyperplasia; diseases related to blood pressure, such as hypertension; or blood flow disorders caused by vasodilation and vasospastic diseases (such as angina, migraine, and Raynaud's disease); vomiting, including chemotherapy-induced nausea and vomiting; and pain or nociception, such as pain or nociception attributed to or associated with any of the above conditions. Finally, the patent describes that these compounds are effective in an amount to be determined in the range of 0.001 mg / kg / day to 100 mg / kg / day.
[0014] It is known that trandipitant can be administered therapeutically by a variety of bioavailable administration routes. U.S. Pat. No. 7,320,994 discloses administration of trandipitant by oral and parenteral routes (e.g., oral), by inhalation, subcutaneously, intramuscularly, intravenously, transdermally, intranasally, rectally, ocularly, topically, sublingually and intrabuccally, with oral administration generally being preferred for treatment.
[0015] Crystal forms IV and V of trandipitant are disclosed in U.S. Pat. No. 7,381,826, and a method for preparing crystal form IV of {2-[1-(3,5-bistrifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone is disclosed in U.S. Pat. Nos. 8,772,496 and 9,708,291. Summary of the invention
[0016] A first aspect of the invention provides a treatment method comprising administering to a patient diagnosed with a tamifluamide-responsive gastrointestinal (GI) disease or condition in an amount and at a frequency of administration sufficient to achieve and maintain a plasma concentration of at least about 100 ng / mL (e.g., above about 125 ng / mL, above about 150 ng / mL, above about 175 ng / mL, above about 200 ng / mL, or above about 225 ng / mL) for the duration of the treatment regimen.
[0017] In this article, reference to patients diagnosed with a gastrointestinal (GI) disease or condition responsive to chuandipitant refers to patients diagnosed with one or more known diseases or conditions in which chuandipitant is described as being useful in treatment, and specifically includes gastric motility disorders (including gastroparesis, delayed gastric emptying, gastric retention in the absence of mechanical obstruction, or other gastric motility disorders) and diseases or conditions exhibiting symptoms selected from the group consisting of nausea, vomiting, early satiety, postprandial fullness, dyspepsia (indigestion), functional dyspepsia, and abdominal pain. In this regard, chuandipitant-responsive GI diseases or conditions include diseases in which improving gastric motility has a therapeutic benefit. Chemotherapy-induced nausea and vomiting (CINV) is another example of a chuandipitant-responsive GI disease or condition.
[0018] As used above and elsewhere herein, the term "about" with respect to a concentration or amount refers to an insignificant difference from the amount that follows. Thus, "about 100 ng / mL" refers to 100±1 ng / mL.
[0019] A second aspect of the present invention provides a method of administering tretinoin to a patient diagnosed with a tretinoin-responsive GI disease or condition, the method comprising: orally administering to the patient a solid immediate-release form of tretinoin at an amount of 100 mg / day to 400 mg / day, 100 mg / day to 300 mg / day, or 100 mg / day to 200 mg / day of tretinoin twice a day, the solid immediate-release form comprising tretinoin and one or more pharmaceutically acceptable excipients. For patients diagnosed with a tretinoin-responsive GI disease or condition, such treatment may be directed to gastric motility disorders (which may include gastroparesis, delayed gastric emptying, gastric retention in the absence of mechanical obstruction, or other gastric motility disorders), chemotherapy-induced nausea and vomiting (CINV), postoperative nausea and vomiting (PONV), and / or any symptom selected from the group consisting of nausea, vomiting, early satiety, postprandial fullness, dyspepsia (indigestion), functional dyspepsia, abdominal distension, and abdominal pain. Treatment may be of a disease or condition in which improving gastric motility has a therapeutic benefit to the patient being treated.
[0020] A third aspect of the present invention provides a method of administering tampamp to a patient diagnosed with a tampamp-responsive GI disease or condition, the method comprising: orally administering a solid immediate-release form of tampamp to a patient once a day in an amount of 150 mg / day to 400 mg / day, 150 mg / day to 300 mg / day, or 150 mg / day to 200 mg / day of tampamp, the solid immediate-release form comprising tampamp and one or more pharmaceutically acceptable excipients. For patients diagnosed with a tampamp-responsive GI disease or condition, such treatment may be directed to gastric motility disorders (which may include gastroparesis, delayed gastric emptying, gastric retention in the absence of mechanical obstruction, or other gastric motility disorders), chemotherapy-induced nausea and vomiting (CINV), postoperative nausea and vomiting (PONV), and / or any symptom selected from the group consisting of nausea, vomiting, early satiety, postprandial fullness, dyspepsia (indigestion), functional dyspepsia, abdominal distension, and abdominal pain. Treatment may be of a disease or condition in which improving gastric motility has a therapeutic benefit to the patient being treated.
[0021] A fourth aspect of the present invention provides a method of administering tampamp to a patient diagnosed with a tampamp-responsive GI disease or condition, the method comprising: orally administering tampamp to a patient in an amount of about 170 mg / day of tampamp. In some embodiments, the amount of 170 mg / day is administered as 85 mg BID, or more specifically as 85 mg Q12H. For patients diagnosed with tampamp-responsive GI diseases or conditions, this treatment may be directed to gastric motility disorders (which may include gastroparesis, delayed gastric emptying, gastric retention in the absence of mechanical obstruction, or other gastric motility disorders), chemotherapy-induced nausea and vomiting (CINV), postoperative nausea and vomiting (PONV), and / or any symptom selected from the group consisting of: nausea, vomiting, early satiety, postprandial fullness, dyspepsia (indigestion), functional dyspepsia, abdominal distension, and abdominal pain. Treatment may be directed to a disease or condition in which improving gastric motility has a therapeutic benefit to the patient being treated.
[0022] The fifth aspect of the present invention provides trandipitant for use in any of the treatment methods described in the preceding aspects.
[0023] The sixth aspect of the present invention provides a pharmaceutical composition comprising trandipitant for use in any of the aforementioned treatment methods.
[0024] The seventh aspect of the present invention provides a method for preparing a pharmaceutical composition comprising the ...
[0025] An eighth aspect of the present invention provides a method of treating gastric dysmotility in an individual, the method comprising: administering to the individual an amount of trandipitant effective to reduce at least one symptom of gastric dysmotility.
[0026] A ninth aspect of the invention provides a method comprising administering to an individual suffering from at least one symptom of gastroparesis or at least one symptom associated with gastroparesis an amount of trandipitant sufficient to alleviate the at least one symptom. The individual may or may not be diagnosed with gastroparesis.
[0027] These and other aspects, advantages and salient features of the invention will become apparent from the following detailed description, which, taken in conjunction with the annexed drawings, discloses embodiments of the invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 Shown are the effects of randipitant on foot-tapping behavior induced by a NK-1 agonist (GR73632, 3 pmol, icv) after oral administration.
[0029] Figure 2Shown are the effects of randipitant on NK-1 agonist (GR 73632, 3 pmol, icv)-induced foot-stamping behavior after oral administration: comparison with other NK-1 antagonists MK-869 and CP-122721: dose response.
[0030] Figure 3 Shown are the effects of randipitant on NK-1 agonist (GR 73632, 3 pmol, icv)-induced foot-stamping behavior after oral administration: comparison with other NK-1 antagonists MK-869 and CP-122721: time course.
[0031] Figure 4 The effects of randipitant on GR73632-induced vocalizations in guinea pigs are shown over a concentration range of 0.05 to 10 mg / kg.
[0032] Figure 5 Shown is the duration of activity following a 0.1 mg / kg dose of tradipitant, ie, inhibition of NK-1 agonist-induced vocalization in guinea pigs.
[0033] Figure 6 Shown are the dose-dependent effects of randipitant in the guinea pig vocalization assay and the effects of various NK-1 antagonists.
[0034] Figure 7 The bar graph shown shows the median daily nausea scores for 64 patients during the 4-week screening period ("Screen") and open-label extension period ("OLE") of the study described in Example 2.2.
[0035] Figure 8 The bar graph shown shows the percentage of days during the screening period ("Screen") and the open-label extension period ("OLE") during which subjects in the study described in Example 2.2 indicated that they were free of nausea (ie, had a nausea score of 0).
[0036] The drawings are intended to depict only typical aspects of the disclosure, and therefore should not be considered to limit the scope of the disclosure. DETAILED DESCRIPTION
[0037] At least one embodiment of the present invention is described below, relating to its application in the treatment of gastrointestinal (GI) diseases or conditions responsive to tampamp using tampamp. Although certain embodiments of the present invention are described in relation to specific diseases such as gastroparesis, it should be understood that the teachings are equally applicable to other gastric motility disorders, which may include delayed gastric emptying, gastric retention or other gastric motility disorders in the absence of mechanical obstruction, chemotherapy-induced nausea and vomiting (CINV), postoperative nausea and vomiting (PONV) and / or any symptom selected from the group consisting of: nausea, vomiting, early satiety, postprandial fullness, dyspepsia (indigestion), functional dyspepsia, abdominal distension and abdominal pain. In patients suffering from tampamp-responsive diseases and conditions, tampamp can be treated by orally administering tampamp in an amount and dosing frequency required to achieve a plasma concentration of at least about 100 ng / mL (e.g., 125 ng / mL or more, 150 ng / mL or more, 175 ng / mL or more, 200 ng / mL or more, or 225 ng / mL or more). Such plasma concentration levels can be achieved, for example, by orally administering to a patient a solid immediate release form of chuandipitant in an amount of 100 mg / day to 400 mg / day, 100 mg / day to 300 mg / day, 100 mg / day to 200 mg / day, or about 85 mg / day to 170 mg / day (which can be administered as, for example, 50 mg bid to 200 mg bid, 50 mg bid to 150 mg bid, 50 mg bid to 100 mg bid, or about 85 mg bid, as described in PCT Publication WO 2016 / 141341A1), wherein the solid immediate release form comprises one or more pharmaceutically acceptable excipients and chuandipitant. Other specific dosages may also be considered part of the present invention.
[0038] As used herein, the terms "patient," "subject," and "individual" refer to humans as well as companion animals (eg, dogs and cats) and other domestic animals (eg, horses, cattle, and sheep). It should be understood that the most preferred patient is a human.
[0039] The present invention further relates to the treatment of GI diseases or conditions responsive to trandipitant, either prophylactically or therapeutically. In addition, the term "treatment" is intended to refer to all processes in which there may be a process of slowing, interrupting, preventing, controlling or stopping the progression of the conditions described herein, and is intended to include preventive treatment of these conditions, but does not necessarily indicate complete elimination of all symptoms of the condition.
[0040] As used herein, in reference to treating a trendipitant-responsive GI disease or condition, the term "effective amount" refers to a dose of trendipitant administered to a patient that is effective for treating the disease or condition.
[0041] With respect to dosage, "qd" refers to once daily dosing; "bid" dosing typically refers to dosing once in the morning and once in the evening, usually separated by no less than about 8 hours or more than about 16 hours, such as 10 to 14 hours or 12 hours (Q12H).
[0042] Those skilled in the art will appreciate that other preferred embodiments may be selected by combining the above preferred embodiments or referring to the examples given herein.
[0043] Example
[0044] 1. Preclinical studies
[0045] Preclinical studies have shown that chuandipitant is a selective neurokinin 1 (NK-1) receptor antagonist. In in vitro functional assays, chuandipitant potently inhibited NK-1 receptor binding and antagonized the effects of NK-1 agonists. In addition, no significant activity was observed in a panel of 74 other receptors, enzymes, and ion channels, including NK-2 and NK-3 receptors. By 3 different measures, chuandipitant is also a potent centrally active NK-1 antagonist in vivo.
[0046] 1.1 Mechanism study
[0047] Cendipitant inhibits 125 I] Substance P (SP) binding to NK-1 receptor expressed by IM-9 cells, K i The K b is 0.095nM (Table 1).
[0048] Table 1. In vitro affinity of trandipitant for NK-1 receptor
[0049]
[0050] These effects are similar to the observed effects of the NK-1 antagonists MK-869 (Aprepitant) and CP-122721. In addition, chuandipitant was evaluated in a panel of 74 other receptors, enzymes, and ion channels. At a test concentration of 1 μM, chuandipitant did not show any inhibition of binding greater than 50%. At NK-2 and NK-3 receptors, the compound did not produce significant inhibition. Therefore, chuandipitant is a highly selective NK-1 antagonist in vitro.
[0051] Several major metabolites of trandipitant were synthesized and tested for their affinity to the NK-1 receptor in a binding assay (Table 2). These metabolites had high affinity to the NK-1 receptor.
[0052] Table 2. In vitro affinity of trandipitant metabolites for NK-1 receptor
[0053] Metabolites name <![CDATA[IM-9 human cell membrane-bound K i (nM)]]> LSN2081070 M2(racemic) 0.09(n=1) LSN2107355 M2(S-enantiomer) 0.08(n=1) LSN2107357 M2(R-enantiomer) 0.94(n=1) LSN2195411 M3 0.03(n=1) LSN2195413 M4(racemic) n=1)
[0054] 1.2 Efficacy Model
[0055] Several in vivo models were used to assess brain NK-1 receptor occupancy and the efficacy of trandipitant.
[0056] 1.2.1 Effects of trandipitant on centrally administered NK-1 agonist-induced foot-stamping behavior in gerbils
[0057] Preface
[0058] Differences in species selectivity of NK-1 receptors present a challenge for the in vivo characterization of NK-1 receptor antagonists. Gerbil NK-1 receptors have been shown to be similar to those of humans (Gitter et al., 1991; Beresford et al., 1991). Gerbils exhibit characteristic programmed foot-stomping behaviors in response to stress, fear, or aversive stimuli (Routtenberg and Kramis, 1967; Holman 1985; Ballard et al., 2001). Intracerebroventricular (icv) administration of substance P or a selective NK-1 receptor agonist (e.g., GR 73632) produces rapid rhythmic hind paw tapping (Graham et al., 1993) that lasts approximately 5 minutes and can be inhibited by systemic administration of brain-penetrating antagonists of the NK-1 receptor (Bristow and Young, 1994; Rupnaik and Williams, 1994). This response is selective for NK-1 agonists, as selective NK-2 and NK-3 agonists do not elicit similar responses (Graham et al., 1993; Li and Iyengar, unpublished). This behavioral response was further characterized and modified to enable the identification and optimization of potent NK-1 receptor antagonists, including trandipitant, in vivo.
[0059] method
[0060] Male Mongolian gerbils weighing 26 to 40 grams (Harlan Sprague Dawley, Indianapolis, IN) were administered the selective neurokinin-1 receptor agonist GR73632 (3 pmol) by direct, vertical, freehand intracerebroventricular (icv) injection using a 27-gauge needle with a sleeve connected to a 50 μl Hamilton syringe to a depth of 4.5 mm below the bregma. Immediately after injection, the animals were individually placed in an isolation chamber with a pressure-sensitive velocimeter platform floor (San Diego Instruments acoustic startle device) that detects and quantifies vibration. The number of foot stamps was recorded for the next 6 to 10 minutes on a PC using the DOS-based "SR" computer program from San Diego Instruments. The raw data were converted using a Microsoft Excel macro that determined the number of events that exceeded a threshold (125) in each 250-millisecond time period within 5.5 minutes after the start of observation. The total number and average intensity of events over the duration were determined. The total number of taps was analyzed using one-way ANOVA and post hoc Dunnett's test using JMP statistical software.
[0061] Initially, a dose-response curve was generated using the NK-1 agonist GR73632 (doses were 0.3, 1, 3, and 10 pmol, icv). The maximal foot-tapping behavior was obtained with the 3 and 10 pmol doses. The 3 pmol dose was subsequently selected as the dose of choice for antagonism experiments.
[0062] NK-1 antagonists were tested for their ability to attenuate GR73632-induced paw stamping. NK-1 antagonists were administered by oral gavage (po) at the doses and time points specified in each experiment. In all tests, all animals received only one dose of NK-1 antagonist.
[0063] ED50 determination / dose response testing
[0064] The NK-1 antagonist can be administered in multiple doses (at least 3 times; one dose per animal) and the response to GR73632 measured.
[0065] Duration of the action test
[0066] NK-1 receptor antagonists including chuandipitant, MK-869 (Aprepitant) and CP-122721 were administered at multiple pretreatment times (once per animal), including 0.5, 1, 2, 4, 7, 16 and 24 hours prior to injection of GR73632 injection (Peninsula Labs, CA) dissolved in saline. chuandipitant was dissolved in 1% CMC / 0.5% SLS / 0.085% PVP vehicle. CP-122721 and MK-869 (Aprepitant) were synthesized at Lilly Laboratories and dissolved in 10% ethanol / Emulphor and 1% CMC / 0.5% SLS / 0.085% PVP, respectively.
[0067] result
[0068] Orally administered tampamp (0.01, 0.03, 0.1, 0.3 mg / kg, po) effectively inhibited the NK-1 agonist (GR 73632, 3 pmol, icv)-induced foot-stamping behavior in gerbils in a dose-dependent manner. Figure 1 ), ED 50 It is 0.03mg / kg. Figure 1 The y-axis data are expressed as the number of foot stamping events within five minutes. The efficacy of trandipitant in this assay was compared with that of other NK-1 antagonists MK-869 and CP-122721 ( Figure 2 ). It was found that chuandipitant was more effective than MK-869 (Merck, ED 50 =0.42mg / kg) and CP-122721 (Pfizer, ED 50 =2.2mg / kg) is more effective.
[0069] Chamdipitant (0.01, 0.03, 0.1, 0.3 mg / kg, po) with an ED of 0.03 + 0.004 mg / kg 50 In contrast, MK-869 inhibited NK-1 agonist foot-stamping behavior at an ED of 0.4+0.05 mg / kg. 50 Paw stamping behavior was inhibited by CP 122721 at doses of 2.2 + 0.5 mg / kg (mean ± SE). Figure 2 The data are expressed as percentage of vehicle control (vehicle response to 3 pmol GR73632).
[0070] It was found that tampon (0.1 mg / kg, po) significantly inhibited NK-1 agonist-induced foot-stamping behavior up to 7 hours after administration ( Figure 3 ), but by 16 hours after administration at this dose, the effect was significantly reduced. However, at a higher dose of 1 mg / kg ( Figure 3 ), tampitant significantly reversed foot-tapping behavior up to 16 hours after administration (greater than 50% inhibition of foot-tapping behavior). Duration of effect of tampitant ( Figure 3 ) was longer than CP-122721 (3 mg / kg), which inhibited foot-tapping behavior up to 2 hours after administration, while MK-869 (1.2 mg / kg, po) significantly inhibited foot-tapping behavior up to 24 hours after administration. Mean ± SE *p<.05 compared to vehicle. Data are expressed as percentage of control of vehicle (vehicle response to 3 pmol GR73632).
[0071] discuss
[0072] The effect of dipitant on NK-1 agonist-induced foot-stamping behavior in gerbils showed that dipitant was a highly potent centrally acting NK-1 receptor antagonist in vivo with a relatively long duration of action.
[0073] 1.2.2: Emetic Challenge Study in Beagles Using Tradipitant
[0074] Preface
[0075] Tandipitant is a potent and selective NK-1 receptor antagonist that has shown efficacy in animal models of stress. Five male dogs were administered a single oral dose of 3 mg / kg MK-869 (positive control), or 0.3, 1.0, and 3.0 mg / kg of Tandipitant in a Latin square design. 0.1 mg / kg of apomorphine (a known emetic) was given intravenously either alone or 2 hours after administration of Tandipitant or MK-869. Different doses were administered to each animal on a specific dosing day, representing each dose of Tandipitant, MK-869, and apomorphine alone. Each animal received each treatment over the five (5) weeks of the study, but only once a week. The purpose of this study was to determine whether Tandipitant inhibits vomiting induced by apomorphine.
[0076] Low doses of trandipitant are ED in the gerbil foot-stamping model of NK-1 receptor antagonism 50 The high dose is 100 times the effective dose and is also the dose of MK-869 determined to be effective for apomorphine-induced emesis in dogs (Gidda, 2003). The medium dose of trandipitant is the approximate half-log interval between the low and high doses.
[0077] The oral route of administration was chosen for trandipitant because this is the route that is clinically recommended or currently used. The intravenous route is typically used for experimental apomorphine administration. Beagles are considered to be an effective species for demonstrating antagonism of apomorphine-induced emesis (Gidda, 2003).
[0078] method
[0079] A single oral dose of 0, 0.3, 1.0 or 3.0 mg of tampitant / kg or 3.0 mg of MK-869 / kg was administered to each male dog once a week in a gelatin capsule. All animals were dosed over five (5) weeks, with each dog receiving one of the five different treatments on each day of dosing. A dose of 0.1 mg of apomorphine / kg was administered by intravenous injection approximately 2 hours after each administration of tampitant or MK-869. In the case of apomorphine administered alone without prior treatment with tampitant or MK-869, apomorphine was administered at approximately the same time as when tampitant or MK-869 was co-administered.
[0080] All dogs were fasted overnight prior to each treatment day and then fed approximately one (1) hour after oral dosing (approximately 1 hour prior to apomorphine administration). Individual doses were adjusted weekly for changes in body weight.
[0081] The dosing regimen consisted of a 5x5 Latin square design, where each subject received 1 dose or dose combination per week (6-day washout), as shown in Table 3 below.
[0082] Table 3. Latin square design
[0083]
[0084] The number of emetic episodes was recorded approximately one hour after apomorphine injection, and plasma concentrations of tradipitant were assessed at the expected Tmax (2 hours after dosing).
[0085] result
[0086] The following table shows the individual, mean and standard deviation values of the 2-hour plasma concentration of zenetipitant. All animals administered zenetipitant had measurable levels 2 hours after administration. In general, plasma concentrations 2 hours after administration increase in a disproportionate manner with increasing doses. As observed in other studies on dogs, exposure to zenetipitant varied between animals. Individual animal data showed that plasma concentrations were unrelated to the number of weeks of administration.
[0087] Table 4. Plasma concentration of chuandipitant (ng / ml)
[0088] Dosage 0.3mg / kg 1.0mg / kg 3.0mg / kg Chamdipitant concentration (ng / ml) Chamdipitant concentration (ng / ml) Chamdipitant concentration (ng / ml) dog 1 51.20 175.58 122.73 dog 2 41.33 86.49 256.58 dog 3 90.93 240.84 316.20 dog 4 83.38 100.97 682.91 dog 5 22.59 61.56 119.79 Mean (SD) 57.89(28.75) 133.09(73.71) 299.64(230.58)
[0089] Vomiting occurred after each treatment, with the highest incidence in the apomorphine-only group. One dog (dog 3) had one vomiting episode with each of the trandipitant and MK-869 doses; this dog also had the highest number of vomiting episodes with apomorphine-only (12). The remaining four (4) dogs did not vomit with any of the trandipitant or MK-869 doses. These dogs had an average of four (4) vomiting episodes with apomorphine-only. The antiemetic effect of MK-869 supports the validity of this model.
[0090] Table 5. Vomiting episodes by treatment group
[0091] Test product* Dose level (mg / kg) Total number of vomiting episodes APO (control) 0 28 MK-869 3.0 1** Tandipitant 0.3 1** Tandipitant 1.0 1** Tandipitant 3.0 1**
[0092] *Apomorphine was administered at the challenge dose to all groups
[0093] **All episodes occurred in the same dog (dog 3)
[0094] The results of this study demonstrated that trandipitant was effective against apomorphine-induced emesis at each dose tested (0.3, 1.0, and 3.0 mg / kg).
[0095] 1.2.3 Inhibition of substance P-induced vocalization by dipitant in guinea pigs
[0096] Preface
[0097] When the NK-1 receptor agonist substance P (SP) is introduced into the brain, it induces stress vocalizations in guinea pigs that can be inhibited by NK-1 antagonists (Kramer et al., 1998; Rupniak et al., 2000). This behavioral assay was used to demonstrate the efficacy and CNS penetration of NK-1 antagonists in guinea pigs, a species with similar receptor affinity for NK-1 antagonists as humans.
[0098] method
[0099] Male Dunkin / Hartley guinea pigs (200 to 250 g) were orally administered vehicle or NK-1 antagonists. Approximately 45 minutes later (for dose response studies), the animals were anesthetized and 0.1 nmol GR73632 (SP analog) in a 5 μl vehicle volume was injected intracerebroventricularly at the intersection of the bregma and the midline of the skull. After 30 minutes of recovery from anesthesia, the animals were placed in a dark test chamber located inside a sound-attenuated cubicle and vocalizations were recorded for 30 minutes. The time spent vocalizing was quantified for each animal. During the duration of the effect study ( Figure 5 ), 0.1 mg / kg of tampretard or vehicle solution was orally administered, and then 2, 4, or 7 hours later, 0.1 nmol of GR73632 was administered intracerebroventricularly as described above. Vocalizations were recorded and quantified as described above. The vehicle solution was CMC ( Figure 4Data) or 10% ethanol / Emulphor, 10% propylene glycol solution ( Figure 5 and 6 ). Data were analyzed using a one-tailed t test.
[0100] result
[0101] Figure 4 The data summarized in show that oral administration of tampitant produced significant inhibition of agonist-induced vocalizations at doses of 10 mg / kg (p<0.001), 1.0 mg / kg (p<0.001), 0.1 mg / kg (p<0.001), and 0.05 mg / kg (p<0.001). The activity of tampitant was not diminished at lower doses, suggesting that even lower doses are required to produce a dose-response function. Figure 4 In the table, the numbers in brackets indicate the percentage of control response.
[0102] Duration of activity studies showed that a single dose of 0.1 mg / kg of tampretard was significantly active in inhibiting agonist-induced vocalizations 7 hours after oral administration of the antagonist compound ( Figure 5 ).
[0103] In the second dose-response study ( Figure 6 ), compared the potency of various NK-1 antagonists in a guinea pig vocalization assay. The vehicle was an ethanol / emulphor solution; vehicle groups were n=5 to 14 for each compound. Lower concentrations of tampitant were tested, and these data are presented together with data obtained using Merck (MK-869) and Pfizer (CP-122721). All NK-1 antagonists tested produced significant vocalization inhibition at a concentration of 1 mg / kg (p<0.001). Only tampitant maintained significant inhibitory activity at 0.1 mg / kg or below and at lower doses of 0.05 and 0.025 mg / kg (p<0.001). The minimum effective dose of tampitant was found to be 0.025 mg / kg, which produced very significant vocalization inhibition compared to the control group (p<0.001).
[0104] discuss
[0105] In guinea pigs, chuandipitant significantly inhibited the vocalization caused by NK-1 agonists, indicating that the compound is an orally available brain-penetrating NK-1 antagonist. The minimum effective dose (MED) for this effect is 0.025 mg / kg. The compound administered orally showed an activity duration of more than 7 hours. In this experimental paradigm, chuandipitant was significantly more potent than MK-869 and CP-122721.
[0106] 1.2.4 NK-1 receptor occupancy
[0107] A tracer NK-1 antagonist compound (GR205171) was used to evaluate the ability of other NK-1 antagonists to occupy brain NK-1 receptors. In these studies, the test compound was administered orally, followed by intravenous administration of the tracer compound. Occupancy of the NK-1 receptor was assessed by quantifying the amount of tracer compound bound to brain NK-1 receptors following increasing doses of the test compound. Using this paradigm, the estimated ED of tradipitant is 50 was 0.04 mg / kg po and was significantly more potent than the other antagonists evaluated.
[0108] 2. Clinical research
[0109] 2.1 Gastrointestinal motility
[0110] A single-center, randomized, double-blind, placebo-controlled study was conducted to investigate the effects of tampitant on small intestinal transit time. A total of 15 healthy subjects (12 males and 3 females) aged 19 to 63 years participated in the study and received at least 1 dose of study medication. A total of 13 subjects completed the study. In each of 3 cycles, subjects were randomized to receive 20 mg of tampitant, 200 mg of tampitant, or placebo as a single oral dose, which was in contrast to a maximum of 1 MBq 111 Four hours after dosing, all subjects received a maximum of 4 MBq 99m Each subject received a total of 3 doses during the study. For all dosing regimens, in vivo gamma scintigraphy studies were performed at predetermined time intervals and the following scintigraphic parameters were analyzed: onset and completion of gastric emptying, onset and completion of colonic arrival, onset and completion of small intestinal transit, and initial and complete disintegration of the capsule (anatomical location and time).
[0111] A statistically significant effect of trandipitant on small intestinal transit time was observed in this study. No effect on gastric emptying was observed in this study. However, this parameter was underestimated in the study.
[0112] 2.2 Gastroparesis
[0113] In the Phase II study of tradipitant in patients with gastroparesis, participants initially entered a 4-week screening period prior to treatment with tradipitant, during which they answered a daily symptom questionnaire that rated the severity of their nausea on a scale of 0 to 5, with 0 indicating no nausea, 1 indicating minimal nausea, 2 indicating mild nausea, 3 indicating moderate nausea, 4 indicating severe nausea, and 5 indicating extremely severe nausea. After the 4-week screening period, patients entered the double-blind, randomized portion of the study, in which they received either 85 mg bid tradipitant or placebo. After 4 weeks of blinded study drug treatment, patients had the opportunity to participate in an additional 8-week open-label extension period, during which each subject received 85 mg bid tradipitant. 64 subjects participated in at least 1 week of the open-label tradipitant dosing portion of the study. Subjects reported average daily recorded nausea scores during the 4-week screening period and during the up to 8-week open-label extension period.
[0114] result
[0115] During the screening period, prior to randomization, subjects reported a mean daily nausea score of approximately 3.20 (± standard deviation 0.83) on a scale of 0 to 5, i.e., greater than "moderate nausea" over 4 weeks. In the open-label portion of the study, during treatment with 85 mg bid trandipitant over a duration of 1 to 8 weeks in the same 64 patients, the same patients reported a mean daily nausea score of approximately 1.63 (± standard deviation 1.17) on a scale of 0 to 5. Figure 7 The median daily nausea scores for the 64 subjects in the screening period (3.19) and the open-label extension period (1.35) are shown. In addition, during the screening period before randomization, subjects reported an average of 9.39% (± standard deviation 14.98) nausea-free days, while during the open-label extension period, subjects reported an average of 45.91% (± standard deviation 33.64) nausea-free days. Figure 8 The median percentage of nausea-free days during the screening period (0%) and the open-label extension period (49.11%) are shown.
[0116] in conclusion
[0117] The above and Figure 7 and 8 The results shown in demonstrated that treatment with 85 mg bid of trandipitant significantly improved the subjects' average daily nausea scores and the number of nausea-free days experienced in subjects with gastroparesis. Administration of 85 mg bid of trandipitant resulted in a reduction of approximately half of the subject-reported average daily nausea scores and a doubling or more of the average percentage of nausea-free days compared to before treatment.
[0118] Implementation
[0119] The invention may be viewed as including, among other illustrative embodiments, one or more of the following illustrative embodiments:
[0120] 1. A method of treating a patient diagnosed with a tampimpetant-responsive gastrointestinal (GI) disease or condition, the method comprising administering to the patient tampimpetant in an amount and at a frequency sufficient to achieve and maintain a plasma concentration of at least about 100 ng / mL, about 125 ng / mL, about 150 ng / mL, about 175 ng / mL, about 200 ng / mL, or about 225 ng / mL during the duration of the treatment regimen.
[0121] 2. The method according to embodiment 1, wherein the trandipitant is orally administered in a solid immediate-release form comprising trandipitant and one or more pharmaceutically acceptable excipients.
[0122] 3. The method according to embodiment 1, wherein the trandipitant is orally administered in a solid controlled-release form comprising trandipitant and one or more pharmaceutically acceptable excipients.
[0123] 4. A method of treating a patient diagnosed with a tamipitant-responsive gastrointestinal (GI) disease or condition, the method comprising orally administering to the patient a solid immediate release form comprising tamipitant and one or more pharmaceutically acceptable excipients twice daily at an amount of 100 mg / day to 400 mg / day, 100 mg / day to 300 mg / day, or 100 mg / day to 200 mg / day of tamipitant.
[0124] 5. A method for treating a patient diagnosed with a tamipitant-responsive gastrointestinal (GI) disease or condition, the method comprising orally administering to the patient once daily a solid immediate release form comprising tamipitant and one or more pharmaceutically acceptable excipients in an amount of 150 mg / day to 400 mg / day, 150 mg / day to 300 mg / day, or 150 mg / day to 200 mg / day of tamipitant.
[0125] 6. A method of treating a patient diagnosed with a tradipitant-responsive gastrointestinal (GI) disease or condition, the method comprising: orally administering tradipitant to the patient in an amount of about 170 mg / day.
[0126] 7. The method of embodiment 6, wherein the amount of 170 mg / day is 85 mg BID.
[0127] 8. The method of embodiment 6, wherein the 170 mg / day amount is 85 mg Q12H.
[0128] 9. The method of any one of embodiments 1 to 8, wherein the transdipitant-responsive GI disease or condition is gastroparesis.
[0129] 10. The method of any one of embodiments 1 to 8, wherein the transdipitant-responsive GI disease or condition is gastric dysmotility.
[0130] 11. The method of any one of embodiments 1 to 8, wherein the transamipitant-responsive GI disease or condition is delayed gastric emptying.
[0131] 12. The method of any one of embodiments 1 to 8, wherein the transdipitant-responsive GI disease or condition is gastric retention in the absence of mechanical obstruction.
[0132] 13. The method of any one of embodiments 1 to 8, wherein the transdipitant-responsive GI disease or condition is a disorder in which improving gastric motility has a therapeutic benefit.
[0133] 14. The method of any one of embodiments 1 to 8, wherein the patient is being treated for at least one symptom selected from the group consisting of nausea, vomiting, early satiety, postprandial fullness, dyspepsia, functional dyspepsia, abdominal bloating, and abdominal pain.
[0134] 15. The method of any one of embodiments 1 to 8, wherein the transdipitant-responsive GI disease or condition is chemotherapy-induced nausea and vomiting.
[0135] 16. The method of any one of embodiments 1 to 8, wherein the transdipitant-responsive GI disease or condition is postoperative nausea and vomiting.
[0136] 17. Tradipitant for use in any of the aforementioned treatment methods.
[0137] 18. A pharmaceutical composition comprising the trandipitant used in any one of the aforementioned methods.
[0138] 19. Tandipitant for use in the preparation of a pharmaceutical composition, the pharmaceutical composition comprising the Tandipitant used in any one of the aforementioned methods.
[0139] 20. A method of treating gastric dysmotility in a subject, the method comprising: administering to the subject an amount of trandipitant effective to reduce at least one symptom of gastric dysmotility, the amount being 170 mg / day.
[0140] 21. The method, the trandipitant or the pharmaceutical composition according to any one of the preceding embodiments, wherein the trandipitant is in crystalline form IV or crystalline form V.
[0141] 22. A method of treatment, comprising: administering to an individual suffering from at least one symptom of gastroparesis an amount of trandipitant sufficient to relieve the at least one symptom of gastroparesis, wherein the amount is 170 mg / day.
[0142] 23. The method of embodiment 22, wherein the symptom of gastroparesis is delayed gastric emptying.
[0143] 24. The method of embodiment 22, wherein the symptom of gastroparesis is nausea.
[0144] 25. The method of embodiment 22, wherein the symptom of gastroparesis is vomiting.
[0145] 26. The method of embodiment 22, wherein the symptom of gastroparesis is early satiety.
[0146] 27. The method of embodiment 22, wherein the symptom of gastroparesis is postprandial fullness.
[0147] 28. The method of embodiment 22, wherein the symptom of gastroparesis is abdominal pain.
[0148] 29. The method of embodiment 22, wherein the symptom of gastroparesis is abdominal bloating.
[0149] 30. The method of embodiment 22, wherein the individual has been diagnosed with gastroparesis.
[0150] 31. The method of embodiment 22, wherein the individual has not been diagnosed with gastroparesis.
[0151] 32. The method of embodiment 22, wherein the individual has been diagnosed with functional dyspepsia.
[0152] 33. The method of embodiment 22, wherein the subject has been diagnosed with functional nausea.
[0153] Although various embodiments are described herein, it should be understood from the specification that various combinations, modifications or improvements of elements may be made therein by those skilled in the art, and they are within the scope of the present invention. In addition, many modifications may be made to adapt specific situations or materials to the teachings of the present invention without departing from the essential scope of the present invention. Therefore, it is not intended that the present invention be limited to the specific embodiments disclosed as the best mode for carrying out the present invention, but the present invention will include all embodiments falling within the scope of the appended claims.
Claims
1. Use of chuandipitant in the manufacture of a medicament for treating gastroparesis, wherein the medicament comprises a solid immediate release dosage form for oral administration to a patient in need thereof, and The solid immediate-release dosage form comprises trandipitant and one or more pharmaceutically acceptable excipients.
2. Use of trandipitant in the manufacture of a medicament for treating nausea caused by gastroparesis, wherein the medicament comprises a solid immediate release dosage form for oral administration to a patient in need thereof, and The solid immediate-release dosage form comprises trandipitant and one or more pharmaceutically acceptable excipients.
3. Use of trandipitant in the manufacture of a medicament for treating symptoms caused by gastroparesis, wherein the medicament comprises a solid immediate release dosage form for oral administration to a patient in need thereof, and The solid immediate-release dosage form comprises trandipitant and one or more pharmaceutically acceptable excipients.
4. The use according to any one of claims 1 to 3, wherein: The solid immediate release dosage forms include capsules.
5. The use according to any one of claims 1 to 4, wherein: The solid immediate-release dosage form comprises 150 mg to 400 mg of trandipitant, and Wherein the treatment comprises oral administration once daily (qd) to a patient in need thereof of a solid immediate release dosage form resulting in a daily dose of 150 mg / day to 400 mg / day.
6. The use according to claim 5, wherein: The solid immediate-release dosage form includes 170 mg of trandipitant, and Wherein the treatment comprises oral administration once daily (qd) to a patient in need thereof of a solid immediate release dosage form resulting in a daily dose of 170 mg / day.
7. The use according to any one of claims 1 to 4, wherein: The solid immediate-release dosage form comprises 50 mg to 200 mg of trandipitant, and Wherein the treatment comprises orally administering to a patient in need thereof a solid immediate release dosage form twice daily (bid), resulting in a daily dose of 100 mg / day to 400 mg / day.
8. The use according to claim 7, wherein: The solid immediate-release dosage form comprises 85 mg of trandipitant, and Wherein the treatment comprises orally administering to a patient in need thereof a solid immediate release dosage form twice daily (bid), resulting in a daily dose of 170 mg / day.
9. The use according to claim 7 or claim 8, wherein: The twice daily (bid) oral administration also includes every 12 hours Q12H oral administration.
10. The use according to any one of claims 1 or 4 to 9, wherein The patient is experiencing symptoms selected from the group consisting of nausea, vomiting, early satiety, postprandial fullness, dyspepsia, functional dyspepsia, abdominal bloating and abdominal pain.
11. The use according to any one of claims 1 or 4 to 9, wherein The patient is experiencing symptoms selected from the group consisting of delayed gastric emptying, nausea, vomiting, early satiety, postprandial fullness, abdominal pain and bloating.
12. The use of any one of claims 2 or 4 to 9, further comprising using the medicament to treat at least one additional symptom of gastroparesis selected from the group consisting of vomiting, early satiety, postprandial fullness, dyspepsia, functional dyspepsia, abdominal distension and abdominal pain.
13. The use of any one of claims 2 or 4 to 9, further comprising using the medicament to treat at least one additional symptom of gastroparesis selected from the group consisting of delayed gastric emptying, vomiting, early satiety, postprandial fullness, abdominal pain and bloating.
14. The use according to any one of claims 3 to 9, wherein: The symptoms caused by gastroparesis are selected from the group consisting of nausea, vomiting, early satiety, postprandial fullness, dyspepsia, functional dyspepsia, abdominal distension and abdominal pain.
15. The use according to any one of claims 3 to 9, wherein: The symptoms caused by gastroparesis are selected from the group consisting of nausea, vomiting, early satiety, postprandial fullness, abdominal pain and abdominal distension.
16. The use according to any one of claims 1 to 15, wherein The chuandipitant is in crystalline form IV or crystalline form V.
Citation Information
Patent Citations
Push-Button Switch Capable of Adjusting Output Power
US20180061593A1
Triazole derivatives as tachykinin receptor antagonists
US7320994B2
Crystalline forms of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
US7381826B2
Intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
US8772496B2
Intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl)-(2-chlorophenyl)-methanone
US9708291B2
